PHARMALINKFHI RENEWS LICENSE AGREEMENT WITH PHASE FORWARD

Waltham, Mass. – March 23, 2006 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced PharmaLinkFHI (PharmaLink), a leading electronic clinical research organization (eCRO), has signed a three-year license agreement to extend its use of Phase Forward's InForm™ Web-based solution for electronic data capture (EDC). A longtime strategic partner, PharmaLink plans to continue to leverage Phase Forward's InForm as one of its primary EDC tools.

With the InForm solution, PharmaLink can help its clients quickly and efficiently access, analyze and report critical clinical data. Because InForm offers enterprise-level scalability - to thousands of sites and tens of thousands of patients - and extensive functionality in an intuitive user interface, clinical development staff can do more faster and with greater accuracy.

"As the leading eCRO conducting all of our trials in EDC, we realized InForm's benefits long ago and have shared many successful implementations with Phase Forward during our strong, six-year partnership," said Richard Staub, president and chief operating officer, PharmaLink. "Because of the increased efficiency it affords, we integrated InForm with our Web-based clinical trial management and reporting system (CTMS), InfoLink. By leveraging the data visibility afforded by our technology platform, combined with our high efficiency clinical processes, we've reduced the time from Last Patient/Last Visit to database lock to between three to eight working days. In addition to its functionality, Phase Forward's worldwide experience will be particularly critical to PharmaLink as we anticipate future global engagements."

"As a firm that's focused on real-time clinical trial management, PharmaLink is at the vanguard of technology adoption," said Bob Weiler, president and chief executive officer, Phase Forward. "The company has pioneered best practices to ensure quality and provide high levels of visibility into the clinical trial process. We are pleased to be working with such a committed partner."